Profile data is unavailable for this security.
About the company
Abbisko Cayman Ltd is a research and development-driven, clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative and differentiated small molecule oncology therapies. The Company's clinical-stage drug candidates include ABSK011 inhibitors, ABSK091 inhibitors, ABSK021 inhibitors and ABSK081 antagonists. The Company's selective preclinical stage drug candidates include ABSK043 inhibitors, ABSK061 inhibitors, ABSK121 inhibitors, ABSK012 inhibitors, ABSK111 inhibitors, ABSK071 inhibitors, ABSK051 inhibitors, and ABSK031 antagonists.
- Revenue in HKD (TTM)695.62m
- Net income in HKD62.78m
- Incorporated2018
- Employees220.00
- LocationAbbisko Cayman LtdBuilding 3, No. 898Halei Road, Zhangjiang Hi-Tech ParkPudong New AreaSHANGHAI 200120ChinaCHN
- Phone+86 2 168912098
- Websitehttps://www.abbisko.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TYK Medicines Inc | 121.60k | -318.29m | 4.10bn | 163.00 | -- | 9.87 | -- | 33,756.94 | -0.8583 | -0.8583 | 0.0003 | 1.09 | 0.0002 | -- | -- | 794.75 | -42.68 | -- | -- | -- | 13.08 | -- | -263,981.30 | -- | -- | -- | 0.3215 | -- | -- | -- | -1.18 | -- | -- | -- |
| Jacobio Pharmaceuticals Group Co Ltd | 228.84m | -51.88m | 4.37bn | 211.00 | -- | 4.44 | -- | 19.08 | -0.067 | -0.067 | 0.2958 | 1.25 | 0.1547 | -- | 7.97 | 890,433.90 | -3.51 | -36.09 | -4.01 | -39.58 | 100.00 | 65.67 | -22.67 | -283.16 | -- | -- | 0.1415 | -- | 145.13 | -- | 56.64 | -- | 29.33 | -- |
| MiRXES Holding Co Ltd | -100.00bn | -100.00bn | 4.55bn | 347.00 | -- | 5.10 | -- | -- | -- | -- | -- | 2.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 3.83 | -- | 0.1682 | -- | -16.14 | -- | -33.37 | -- | -- | -- |
| Laekna Inc | 0.00 | -273.00m | 5.02bn | 84.00 | -- | 5.66 | -- | -- | -0.7423 | -0.7423 | 0.00 | 1.99 | 0.00 | -- | -- | 0.00 | -27.79 | -- | -34.25 | -- | -- | -- | -- | -- | -- | -- | 0.1383 | -- | -- | -- | 31.05 | -- | -- | -- |
| Edding Genor Group Holdings Ltd | 254.56m | 22.89m | 5.12bn | 17.00 | 56.76 | 1.08 | 146.75 | 20.12 | 0.0451 | 0.0451 | 0.4902 | 2.38 | 0.1724 | -- | 5.21 | 10,606,700.00 | 1.46 | -48.63 | 1.72 | -55.19 | 99.56 | 97.88 | 8.45 | -2,303.07 | -- | -- | 0.0007 | -- | -- | 73.71 | 92.40 | -- | -43.79 | -- |
| CARsgen Therapeutics Holdings Ltd | 95.51m | -593.11m | 6.95bn | 371.00 | -- | 6.42 | -- | 72.73 | -1.08 | -1.08 | 0.1736 | 1.90 | 0.0465 | 5.13 | 7.63 | 204,083.10 | -28.88 | -76.51 | -32.44 | -89.25 | 50.57 | -- | -621.16 | -12,640.86 | 6.40 | -- | 0.0672 | -- | -- | -- | -6.73 | -- | -28.32 | -- |
| Lepu Biopharma Co Ltd | 796.00m | -201.37m | 7.36bn | 546.00 | -- | 8.24 | -- | 9.25 | -0.1177 | -0.1177 | 0.4653 | 0.4951 | 0.2917 | 2.35 | 18.33 | 1,598,400.00 | -8.24 | -24.70 | -14.39 | -37.71 | 88.41 | -- | -28.26 | -459.37 | 0.5915 | -5.03 | 0.5632 | -- | 63.21 | -- | -1,761.77 | -- | -29.86 | -- |
| Abbisko Cayman Ltd | 695.62m | 62.78m | 7.50bn | 220.00 | 127.77 | 3.43 | 19.40 | 10.78 | 0.0873 | 0.0873 | 1.10 | 3.25 | 0.2745 | -- | -- | 3,161,906.00 | 2.48 | -24.40 | 2.83 | -25.96 | 100.00 | 100.00 | 9.03 | -229.19 | -- | -- | 0.1363 | -- | 21.45 | -- | 95.21 | -- | -- | -- |
| Alphamab Oncology | 893.17m | 264.57m | 7.68bn | 484.00 | 30.08 | 3.61 | 22.22 | 8.60 | 0.2636 | 0.2636 | 0.8975 | 2.20 | 0.3492 | 0.8254 | 23.76 | 2,126,606.00 | 10.35 | -9.96 | 12.30 | -11.75 | 92.27 | -- | 29.62 | -103.28 | 4.75 | -- | 0.1285 | -- | 192.58 | -- | 178.99 | -- | -33.81 | -- |
| GenFleet Therapeutics (Shanghai) Inc | 219.84m | -1.05bn | 9.27bn | 94.00 | -- | -- | -- | 42.19 | -3.05 | -3.05 | 0.6366 | -8.69 | -- | -- | -- | -- | -- | -- | -- | -- | 80.86 | -- | -479.17 | -- | 0.1655 | -23.43 | -- | -- | 42.00 | -- | -33.31 | -- | -- | -- |
| Suzhou Ribo Life Science Co Ltd | 204.71m | -250.84m | 10.40bn | 404.00 | -- | -- | -- | 50.82 | -1.55 | -1.55 | 1.27 | -0.4107 | -- | -- | -- | -- | -- | -- | -- | -- | 90.90 | -- | -131.95 | -- | 0.9173 | -14.93 | 0.8949 | -- | 324,052.30 | -- | 36.93 | -- | -- | -- |
| Nanjing Leads Biolabs Co Ltd | 0.00 | -326.39m | 10.86bn | 192.00 | -- | 86.38 | -- | -- | -2.01 | -2.01 | 0.00 | 0.632 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.01 | -- | 0.7407 | -- | -100.00 | -- | 16.85 | -- | -- | -- |
Data as of Mar 04 2026. Currency figures normalised to Abbisko Cayman Ltd's reporting currency: Hong Kong Dollar HKD
13.53%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Allianz Global Investors Asia Pacific Ltd.as of 21 Nov 2025 | 39.24m | 5.77% |
| The Vanguard Group, Inc.as of 31 Jan 2026 | 18.05m | 2.66% |
| Fidelity Management & Research (Hong Kong) Ltd.as of 31 Dec 2025 | 8.49m | 1.25% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 6.19m | 0.91% |
| BlackRock Advisors LLCas of 31 Jan 2026 | 4.43m | 0.65% |
| Value Partners Ltd.as of 30 Jun 2025 | 4.41m | 0.65% |
| Green Court Capital Management Ltd.as of 31 Dec 2025 | 3.47m | 0.51% |
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 2.97m | 0.44% |
| BlackRock Advisors (UK) Ltd.as of 06 Feb 2026 | 2.43m | 0.36% |
| OrbiMed Advisors LLCas of 31 Jan 2026 | 2.31m | 0.34% |
More ▼
Data from 30 Jun 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
